Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: A trial of the German Dermatologic Cooperative Oncology Group

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 1, 2012, Pages 48-53

  Pflugfelder, A ^a   Welter, A K ^a   Leiter, U ^a   Weide, B ^a   Held, L ^a   Eigentler, T K ^a   Dirschka, T ^b   Stockfleth, E ^c   Nashan, D ^d   Garbe, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Dermatological Practice Centre   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HYALURONIC ACID;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EROSION; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN EDEMA; SKIN TOXICITY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; FEMALE; GERMANY; HUMANS; HYALURONIC ACID; KERATOSIS, ACTINIC; MALE; MIDDLE AGED;

EID: 83955162958     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04005.x     Document Type: Article

References (24)

1. Salasche SJ,. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42 (1 Pt 2): 4-7.
2. Frost CA, Green AC,. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-464. (Pubitemid 24315411)
3. Moy RL,. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42 (1 Pt 2): 8-10.
4. Ackerman AB, Mones JM,. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22. (Pubitemid 43876387)
5. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis. Neoplasia 2001; 3: 53-61. (Pubitemid 32201610)
6. Wang D, Dubois RN,. Prostaglandins and cancer. Gut 2006; 55: 115-122. (Pubitemid 41820645)
7. Adamson DJ, Frew D, Tatoud R, et al. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002; 61: 7-12. (Pubitemid 34049506)
8. Eberle J, Fecker LF, Forschner T, Ulrich C, Rowert-Huber J, Stockfleth E,. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 2007; 156 (Suppl. 3): 18-24. (Pubitemid 46632507)
9. Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007; 156 (Suppl. 3): 25-33. (Pubitemid 46632508)
10. Brown MB, Jones SA,. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 2005; 19: 308-318. (Pubitemid 40691707)
11. Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995; 82: 19-26.
12. McCourt PA, Ek B, Forsberg N, et al. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994; 269: 30081-30084. (Pubitemid 24376465)
13. Wolf JE Jr, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713. (Pubitemid 34023642)
14. Rivers JK, McLean DI,. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-1242. (Pubitemid 27443816)
15. Gebauer K, Brown P, Varigos G,. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-43. (Pubitemid 36246421)
16. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-407.
17. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100. (Pubitemid 34158414)
18. Smith SR, Morhenn VB, Piacquadio DJ,. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156-159.
19. Lewis V, Finlay AY,. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180. (Pubitemid 38457276)
20. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
21. Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl. 3): 8-12. (Pubitemid 46632512)
22. Cockerell CJ,. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42 (1 Pt 2): 11-17.
23. Dirschka T, Bierhoff E, Pflugfelder A, et al. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol 2010; 24: 258-263.
24. Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-659.